NOTE
13 – SEGMENT REPORTING
| A. | Information
about reported segment profit or loss and assets |
As
of March 31, 2026, the Company has two reportable segments: (i) Biotechnology activity, and (ii) Renewable energy projects. The Biotechnology
operating segment consists of MitoCareX from the acquisition date, and the Renewable energy projects operating segment consists of NITO
Renewable Energy, Inc. and Solar photovoltaic joint venture project.
The
CODM evaluates performance and allocates resources based primarily on segment operating loss. Prior period segment information has been
recast to conform to the current year presentation.
The
following table presents information about the Company’s reportable segments for the three months ended March 31, 2026 and 2025:
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| | |
2026 | | |
2025 | |
| | |
Three months ended | |
| | |
March 31 | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Revenue from biotechnology activity | |
| - | | |
| - | |
| Cost related to biotechnology activity (*) | |
| (125 | ) | |
| - | |
| Salaries and related expenses related to biotechnology activity | |
| (256 | ) | |
| - | |
| Amortization of intangible asset | |
| (100 | ) | |
| - | |
| Operating loss from Biotechnology activity | |
| (481 | ) | |
| - | |
| | |
| | | |
| | |
| Revenue from renewable energy projects | |
| - | | |
| - | |
| Cost related to renewable energy projects | |
| (4 | ) | |
| (71 | ) |
| Operating loss from renewable energy projects | |
| (4 | ) | |
| (71 | ) |
| | |
| | | |
| | |
| Professional services | |
| (423 | ) | |
| (238 | ) |
| Share base compensation | |
| (1,149 | ) | |
| (41 | ) |
| Change in fair value of contingent consideration | |
| 343 | | |
| - | |
| Goodwill impairment | |
| (6,291 | ) | |
| - | |
| Depreciation | |
| (3 | ) | |
| - | |
| Other general and administrative expenses | |
| (217 | ) | |
| (153 | ) |
| Total Operating loss | |
| (8,225 | ) | |
| (503 | ) |
| | |
| | | |
| | |
| Interest of loans | |
| - | | |
| (77 | ) |
| Financing expenses, net | |
| (100 | ) | |
| (639 | ) |
| Other income | |
| 386 | | |
| - | |
| Changes in fair value of investments measured under the fair value option | |
| 492 | | |
| 103 | |
| Income taxes | |
| 23 | | |
| - | |
| Net loss | |
| (7,424 | ) | |
| (1,116 | ) |
| (*) | | Costs
related to biotechnology activity primarily consist of subcontractors engaged in research and development activities. |
|